Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical use of sophoricoside

A technology of sophorin and medicine, which is applied in the field of pharmaceutical application of sophorin, and can solve the problems of increasing the incidence of breast cancer and endometrial cancer

Inactive Publication Date: 2009-04-01
杜宁
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, the intake of human estrogen also has many side effects, the most serious being the increased incidence of breast cancer and endometrial cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of sophoricoside
  • Pharmaceutical use of sophoricoside
  • Pharmaceutical use of sophoricoside

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Embodiment 1: Animal grouping and modeling

[0048] Sixty-six 6-month-old female SD rats were randomly divided into model group (ovariectomized, OVX), sham operation group (SHAM), and various drug intervention groups: ERT group, selective estrogen receptor modulator (SERM) group, cents Linggubao group, Sophoroside 10 mg group (HDA10), Sophoroside 20 mg group (HDA20), Sophoroside 40 mg group (HDA40), Sophoroside 80 mg group (HDA80).

[0049] 1. Modeling method:

[0050]OVX group and each drug intervention group: 1% pentobarbital sodium solution, 5ml / kg, intraperitoneally injected, after the anesthesia took effect, the rats were placed in a prone position, the hair was removed at the third lumbar vertebra under the costal arch, and benzalkonium bromide was administered. Disinfect the skin with ammonium tincture, cut the skin, incision about 1cm long, cut the subcutaneous and fascia, bluntly separate the muscles, carefully incise the peritoneum, extend the tissue forceps ...

Embodiment 2

[0066] Embodiment 2: Rat body weight and uterine wet weight before and after the experiment

[0067] The body weight of the rats was weighed before and after the experiment, and the wet weight was taken from the uterus at the same time when the samples were sacrificed. The results are shown in Table 1.

[0068] Table 1 Rat body weight and uterine wet weight before and after the experiment (x±S x )

[0069]

[0070] Note: Compared with the SHAM group: ** P* P<0.05; compared with OVX group: △△P<0.01, △P<0.05.

[0071] Statistical analysis of variance was used to analyze the data. There was a large difference in uterine wetness in the SHAM group, which was considered to be caused by different menstrual cycles. There was no statistical difference in body weight among the groups before and after the experiment. There was a statistically significant difference in uterine wet weight between the ovariectomized groups and the SHAM group (P0.05), suggesting that estrogen has a st...

Embodiment 3

[0072] Embodiment 3: Observation of uterine slices:

[0073] 1. Embedding: Fix the rat uterus obtained in Example 1 with 4% paraformaldehyde for 24 hours; 75% alcohol dehydration overnight; 85% alcohol dehydration for 45 minutes; 95% alcohol dehydration for 45 minutes × 2; 100% alcohol dehydration for 45 minutes minutes × 2; immerse in xylene for 15 minutes × 2; oven at 65°C, soak in wax for 3 hours; embedding in paraffin.

[0074] 2. Slicing: take the coronal surface of rat uterine lumen, slice it with a paraffin microtome (Leica, Model: RM2235), 5 μm in thickness, put it in warm water at 30° C., and treat the slide with polylysine. Bake the slices in a 65°C oven for 3 hours and slice them for later use.

[0075] 3. HE staining of the uterus: 1) Dewax the slices to water: 65°C oven for 3 hours; immerse in xylene for 10 minutes × 3; 100% alcohol for 10 minutes × 2; 95% alcohol for 10 minutes × 2; 85% alcohol for 10 minutes; 75% alcohol for 10 minutes; double distilled water....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of sophoricoside in the preparation of a drug for preventing and / or remedying postmenopausal female articular cartilage degeneration or osteoarthritis. The sophoricoside has obvious curative effect, does not have side effects on uterus, breast and the like caused by animal estrogen, is convenient for extracting and has abundant sources and wide market prospect.

Description

technical field [0001] The invention relates to the application of sophoridoside in the preparation of medicines for preventing and / or treating articular cartilage degeneration and osteoarthritis in postmenopausal women. Background technique [0002] Osteoarthritis (OA) is the most common bone and joint disease in middle-aged and elderly people. Its onset and progression are affected by age, hormones, environment, genes and other factors. The main pathological manifestation is cartilage defect in the synovial joint. The incidence of postmenopausal women is higher than that of men, and the incidence of osteoarthritis in women with low estrogen levels increases (sowers MR, McConnell D, Jannausch M, etc., Estradiol and its metabolites and their association with knee osteoarthritis Arthritis Rheum. 2006 8; 54 (8 ):2481-7), suggesting that estrogen plays a role in the pathogenesis of osteoarthritis. Estrogen acts by binding to estrogen receptor ER in joints, and is expressed in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P19/02A61P29/00A61P15/12
CPCA61K31/7048A61P15/12A61P19/00A61P19/02A61P29/00
Inventor 杜宁高峰
Owner 杜宁
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com